All In Biotech

Investigational drug · Phase 3

Tucidinostat

Also called: Chidamide, HBI-8000, SHR2554 analog, CS055

Not approved by FDA. In 9 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy, Unresectable or Metastatic Melanoma, Progressive Brain Metastasis.

Phase 3

Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

9

8 still active

All registered trials

275

Any phase or sponsor naming "Tucidinostat"

First trial start

2021

Apr 13, 2021

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Tucidinostat", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy
  • Unresectable or Metastatic Melanoma
  • Progressive Brain Metastasis
  • Relapsed/Refractory Peripheral T Cell Lymphoma
  • Lymphoma, T-Cell, Peripheral
  • Relapsed or Refractory Peripheral T-cell Lymphoma
  • Peripheral T-cell Lymphoma
  • Colorectal Cancer
  • Peripheral T Cell Lymphoma
  • Non Small Cell Lung Cancer

Approved drugs for the same conditions: Small cell lung cancer · Colorectal cancer · Melanoma · Oncology · Hematology and blood cancers

Largest trials

Live from ClinicalTrials.gov: studies naming "Tucidinostat" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 562 on PubMed

Also in development for Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy

  • AdabelimumabSHR-A2102, SHR2554Phase 320 trials

    Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.